AAAna Teresa Amaral

Ana Teresa Amaral

*This is an algorithmically generated author record based on publicly available information.

Ana Teresa Amaral has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    USE OF PHYTOTHERAPY IN PORTUGAL

    by Rui Aguiar, Alexandra Martins, Sonia Scholz, Teresa Amaral, Joana Frazao

    The objective of this work is to better understand the use of plants and herbal products for medicinal purposes in Portuguese households, namely which plants are most used and which health conditions are most targeted. It also seeks to evaluate the attitudes and habits related to this use, its role in their health management, the sources of information used and the frequency of consultation with professionals specialized in the area. A descriptive cross-sectional study was conducted using an online questionnaire. A total of 210 responses were obtained. 78% of the respondents were female. 71.9% of the respondents had a university degree. 41.4% reported having salary above € 1000 and 27.1% above € 2000. The mean age in the sample was 50.8 years. More than 50% of the respondents reported using medicinal plants in the flu and cough, to aid digestion and to aid sleep. The plants with more respondents were eucalyptus and peppermint (in respiratory conditions), lemon balm (in digestive and nervous conditions), chamomile (in respiratory, digestive and skin conditions), linden (in respiratory and nervous conditions), rosemary (for digestive, circulatory and nervous diseases) and arnica (for joint and skin diseases). The most common form of use was infusion (87.6%), followed by essential oils (51.0%), tablets or similar forms (48.1%) and external forms (46.7%). The most frequent places of acquisition of medicinal plants were the stores of natural products (71.4%). 31.4% of the respondents put medicinal plants as the first option in their health management, and 30.5% said they used them together with conventional medicines. The main sources of information for decisions on this topic mentioned by the sample were family knowledge (54.8%), consultations with naturopaths and similar (41.9%), counseling with friends (37.1%), specialized means in natural health (35.2%) and generalist means (34.3%). 23.8% of the respondents said they make consultations with phytotherapy professionals or naturopaths, while 23.3% said they do it only in severe cases. This study found a substantial use of medicinal plants in Portugal, especially for the mildest health conditions and with the safest plants. The evaluation of the answers in the face of scientific knowledge about the properties of plants points to a mostly correct use. However, the issues of adverse reactions, contraindications and drug interactions were not addressed in this study. We recognize that a reasonably detailed web questionnaire is answered mainly by the people with the most interest in the subject, and therefore the sample obtained may not be representative of the general Portuguese population. Bearing in mind that fact, this study will still provide useful information the most used plants and target conditions, as well as on the usage patterns of the people who use them the most. The objective of this work is to better understand the use of plants and herbal products for medicinal purposes in Portuguese households, namely which plants are most used and which health conditions are most targeted. It also seeks to evaluate the attitudes and habits related to this use, its role in their health management, the sources of information used and the frequency of consultation with professionals specialized in the area. A descriptive cross-sectional study was conducted using an online questionnaire. A total of 210 responses were obtained. 78% of the respondents were female. 71.9% of the respondents had a university degree. 41.4% reported having salary above € 1000 and 27.1% above € 2000. The mean age in the sample was 50.8 years. More than 50% of the respondents reported using medicinal plants in the flu and cough, to aid digestion and to aid sleep. The plants with more respondents were eucalyptus and peppermint (in respiratory conditions), lemon balm (in digestive and nervous conditions), chamomile (in respiratory, digestive and skin conditions), linden (in respiratory and nervous conditions), rosemary (for digestive, circulatory and nervous diseases) and arnica (for joint and skin diseases). The most common form of use was infusion (87.6%), followed by essential oils (51.0%), tablets or similar forms (48.1%) and external forms (46.7%). The most frequent places of acquisition of medicinal plants were the stores of natural products (71.4%). 31.4% of the respondents put medicinal plants as the first option in their health management, and 30.5% said they used them together with conventional medicines. The main sources of information for decisions on this topic mentioned by the sample were family knowledge (54.8%), consultations with naturopaths and similar (41.9%), counseling with friends (37.1%), specialized means in natural health (35.2%) and generalist means (34.3%). 23.8% of the respondents said they make consultations with phytotherapy professionals or naturopaths, while 23.3% said they do it only in severe cases. This study found a substantial use of medicinal plants in Portugal, especially for the mildest health conditions and with the safest plants. The evaluation of the answers in the face of scientific knowledge about the properties of plants points to a mostly correct use. However, the issues of adverse reactions, contraindications and drug interactions were not addressed in this study. We recognize that a reasonably detailed web questionnaire is answered mainly by the people with the most interest in the subject, and therefore the sample obtained may not be representative of the general Portuguese population. Bearing in mind that fact, this study will still provide useful information the most used plants and target conditions, as well as on the usage patterns of the people who use them the most.

  • Open Access

    EWS::FLI1-DHX9 interaction promotes Ewing sarcoma sensitivity to DNA topoisomerase 1 poisons by altering R-loop metabolism

    by Joaquin Olmedo-Pelayo, Esperanza Granado-Calle, Daniel Delgado-Bellido, Laura Lobo-Selma, Carmen Jordán-Pérez, Ana T. Monteiro-Amaral, Anna C. Ehlers, Shunya Ohmura, Angel M. Carcaboso, Javier Alonso, et al.

    Drug resistance is one of the major factors associated with poor outcome of cancer patients. Treatment of Ewing sarcoma (EwS), an aggressive neoplasm mainly affecting children, adolescents and young adults, is associated with therapy failure and tumor relapse in 30-80% of the cases. Thus, it supports the need to explore the mechanisms modulating drug activity. Here, we describe a novel mechanism of drug sensitivity based on the role of EWS::FLI1 in R-loop metabolism. Our results demonstrate that EWS::FLI1 promotes R-loop formation favoring the interaction between DHX9 and elongating RNA polymerase II. In addition, we discovered that EWS::FLI1 kidnaps DHX9 preventing the resolution of TOP1 poisoning-associated R-loops. Our findings indicate that R-loops accumulation promotes replicative stress, genome instability and cell sensitivity to SN-38. Collectively, these results uncover a novel mechanism behind EwS sensitivity to genotoxic agents, with relevant implications for EwS treatment.


  • Open Access

    Hippo pathway effectors YAP1/TAZ induce a EWS-FLI1-opposing gene signature and associate with disease progression in Ewing Sarcoma

    by Pablo Rodríguez-Núñez, Laura Romero-Pérez, Ana T. Amaral, Pilar Puerto-Camacho, Carmen Jordán, David Marcilla, Thomas G. P. Grunewald, Enrique de Alava, Juan Díaz-Martín

    YAP1 and TAZ (WWTR1) oncoproteins are the final transducers of Hippo tumor suppressor pathway. Deregulation of the pathway leads to YAP1/TAZ activation fostering tumorigenesis in multiple malignant tumor types, including sarcoma. However, oncogenic mutations within the core components of the Hippo pathway are uncommon. Ewing Sarcoma (EwS), a pediatric cancer with low mutation rate, is characterized by a canonical fusion involving EWSR1 gene, and FLI1 as the most common partner. The fusion protein is a potent driver of oncogenesis but secondary alterations are scarce, and little is known about other biological factors that determine the risk of relapse or progression. We have observed YAP1/TAZ expression and transcriptional activity in EwS cell lines. Analyses of 55 primary human EwS samples revealed that high YAP1/TAZ expression was associated with progression of the disease and predicted poorer outcome. We did not observe recurrent SNV or copy number gains/losses in Hippo pathway-related loci. However, differential CpG methylation of RASSF1 locus -a regulator of Hippo pathway- was observed in EwS cell lines compared with mesenchymal stem cells, the putative cell of origin of EwS. Hypermethylation of RASSF1 correlated with the transcriptional silencing of the tumor suppressor isoform RASFF1A , and transcriptional activation of the protumorigenic isoform RASSF1C promoting YAP1/TAZ activation. Knockdown of YAP1/TAZ decreased proliferation and invasion abilities of EwS cells, and revealed that YAP1/TAZ transcription activity is inversely correlated with the EWS-FLI1 transcriptional signature. This transcriptional antagonism could be partly explained by EWS-FLI1-mediated transcriptional repression of TAZ. Thus, YAP1/TAZ may override the transcriptional program induced by the fusion protein, contributing to the phenotypic plasticity determined by dynamic fluctuation of the fusion protein, a recently proposed model for disease dissemination in EwS.


  • Innovative Therapies in Ewing Sarcoma

    by Ana Teresa Amaral, José Luis Ordóñez, Ana Pastora Otero-Motta, Daniel J. García-Domínguez, María Victoria Sevillano, Enrique de Álava

    Ewing Sarcoma is a developmental tumor characterized by balanced chromosomal translocations and formation of new fusion genes, which are the main hallmark of this rare entity. Despite the vast knowledge regarding the molecular aspects of this rare malignancy obtained in the last few years, including the discovery of new therapeutic targets, many questions still remain open. In this review we focus on the research on targeted therapies in this malignancy, and discussed some bottlenecks related to this such as the possible role of pathologists, the availability of samples, the lack of appropriate animal models, and the resources needed to carry out preclinical and clinical research.